GI Hepatobiliary

Hepatocellular Carcinoma

Localized

No Prior Therapy

1st Line

IRB #2377
A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma

No Trials Currently Available

IRB # 19185
Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)

2nd line

Prior Therapy

IRB # 17603
Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma

No Trials Currently Available

Cholangiocarcinoma

1st Line

IRB # 19095
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

1st or 2nd Line

New study to be available soon

CROSS-DISEASE TRIALS:

IRB# TBD
EAY131
(MATCH)

http://www.ohsu.edu/research/rda/so/knight.php

OHSU